James Hardie exceeded fourth quarter and full-year guidance with adjusted EBITDA of $381M and $1.27B respectively, despite organic sales declining 2% amid market headwinds. The company provided FY27 outlook targeting 4-8% pro forma adjusted EBITDA growth and free cash flow above $500M, while indicating it will achieve cost synergy targets ahead of the original three-year timeline following the AZEK acquisition.